Welcome to our dedicated page for The Oncology Institute news (Ticker: TOI), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute reports developments in value-based community oncology care, combining oncology and hematology services with specialty pharmacy, patient services, clinical trials, transfusions, and related care models. Its updates center on operating results, specialty pharmacy volume, gross profit and cash flow trends, and the performance of capitated and Medicare Advantage payor relationships.
Company news also covers participation in CMS oncology payment models, contract expansion across community oncology markets, clinical pathway and provider engagement initiatives, investor conference appearances, and governance or compliance leadership changes. The business operates through Specialty Pharmacy, Patient Services, and Clinical Trials and Other segments.
The Oncology Institute (TOI) has successfully completed its merger with DFP Healthcare Acquisitions Corp., with the transaction approved on November 12, 2021. This merger establishes TOI as a public company, trading under the new ticker symbols 'TOI' and 'TOIIW' on NASDAQ. The transaction values TOI at $842 million, with a significant cash infusion of approximately $334 million, including $275 million from a private placement. The funds will support expansion initiatives across multiple states, driving TOI's value-based oncology care strategy.